Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment his Department has made of the adequacy of treatment and provision of support through the NHS for patients of neuroendocrine cancer.

NHS England has made an assessment of the need for national treatment decisions as to the commissioning of systemic therapies for neuroendocrine carcinomas. Based on this assessment, it has discussed the issue with the National Institute for Health and Care Excellence (NICE) and NICE has agreed to do a multiple technology appraisal of lanreotide, sunitinib, everolimus and peptide receptor radionuclide therapy. NICE guidance on these treatments is due in the summer of 2017. In the meantime, sunitinib is available from the Cancer Drugs Fund and lanreotide is available through routine commissioning.